Increased circulating RANTES in type 2 diabetes

Dworacka, Marzena; Krzyżagórska, Ewa; Iskakova, Saule; Bekmukhambetov, Yerbol; Urazayev, Olzhas; Dworacki, Grzegorz

doi:10.1684/ecn.2014.0355

Cited by 20 publications

(16 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This finding is similar to our previous results that RANTES levels were significantly higher in type 2 diabetes patients with hypertriglyceridemia compared with controls [8], and aligns with some other studies indicating that circulating RANTES levels were significantly higher in patients with dyslipidemia [21], hyperglycemia [22, 23], or metabolic syndrome [24] compared with controls. Our present study also documented that PFP RANTES levels were positively correlated with the levels of TC, TG, FBG, 2hPG, and HbA1c, but negatively related to the levels of HDL-C, which supported that RANTES might be associated with disorders of metabolism.…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Atorvastatin Decreased Circulating RANTES Levels in Impaired Glucose Tolerance Patients with Hypercholesterolemia: An Interventional Study

Gao

Jia

et al. 2017

Diabetes Ther

View full text Add to dashboard Cite

IntroductionImpaired glucose tolerance (IGT) is the major cause of the development of both type 2 diabetes and atherosclerosis. Regulated upon activation, normal T cells expressed and secreted (RANTES), a proinflammatory chemokine, is associated with atherosclerosis. We investigated the effect of atorvastatin on circulating RANTES in IGT patients with hypercholesterolemia.MethodsThis study evaluated cross-sectional and interventional studies of 32 IGT patients with hypercholesterolemia (group A) and 32 controls (group B). Group A was treated with atorvastatin (20 mg/day) for 8 weeks. Platelet-free plasma (PFP) RANTES and clinical characteristics were examined.ResultsPFP RANTES was significantly higher in group A compared with group B (9.76 ± 3.10 vs 6.43 ± 2.16 ng/ml, P < 0.001). PFP RANTES was positively correlated with total cholesterol (TC) (r = 0.589, P < 0.001), low-density lipoprotein cholesterol (LDL-C) (r = 0.583, P < 0.001), triglycerides (TG) (r = 0.450, P < 0.001), fasting blood glucose (FBG) (r = 0.469, P < 0.001), 2-hour postchallenge glucose (2hPG) (r = 0.397, P = 0.001), glycosylated hemoglobin (HbA1c) (r = 0.353, P = 0.004), and high sensitivity C-reactive protein (hsCRP) (r = 0.616, P < 0.001), and negatively related to high-density lipoprotein cholesterol (HDL-C) (r = −0.272, P = 0.029). After controlling for confounders, LDL-C (β = 2.109, P < 0.001) and hsCRP (β = 0.272, P = 0.029) were independently related to RANTES. After atorvastatin treatment, PFP RANTES significantly decreased in group A compared with baseline (from 9.76 ± 3.10 to 7.48 ± 2.78 ng/ml, P < 0.001).ConclusionsAtorvastatin decreased circulating RANTES in IGT patients with hypercholesterolemia, indicating that statins may play an important role in inhibiting inflammatory responses in patients with IGT.

show abstract

Section: Discussionsupporting

confidence: 92%

“…In addition, RANTES has been involved in developing abnormal glucose metabolism. Patients with IGT or with type 2 diabetes presented increased RANTES levels compared with controls [8, 22, 23]. Moreover, the high levels of RANTES were related to the development of type 2 diabetes independently of metabolic syndrome-related risk factors [22].…”

Section: Discussionmentioning

confidence: 99%

Atorvastatin Decreased Circulating RANTES Levels in Impaired Glucose Tolerance Patients with Hypercholesterolemia: An Interventional Study

Gao

Jia

et al. 2017

Diabetes Ther

View full text Add to dashboard Cite

show abstract

“…These chemokines are proinflammatory mediators that control the trafficking of immune inflammatory cells, such as monocytes, macrophages and dendritic cells. Previous studies carried out on obese humans reported increased levels of chemokines, as well as increased infiltration of macrophages, in the adipose tissue, which were concomitant with an enhanced inflammatory response, insulin resistance and type 2 diabetes [38,39].…”

Section: Parametersmentioning

confidence: 92%

CCL2, CCL5, IL4 and IL15 Gene Polymorphisms in Women with Gestational Diabetes Mellitus

et al. 2016

View full text Add to dashboard Cite

Gestational diabetes mellitus (GDM) is a glucose intolerance that occurs during pregnancy. Several studies suggest that inflammation contributes to pregnancy-induced insulin resistance and the development of glucose intolerance. The aim of this study is to examine the association between the ,, and gene polymorphisms and the development of GDM. This study included 411 pregnant women who underwent a 75 g oral glucose tolerance test at 24-28 weeks of gestation. Participants were categorised into 2 groups according to results of the oral glucose tolerance test (OGTT). The GDM group included 204 pregnant women who were diagnosed with GDM. The normal glucose tolerance group included 207 pregnant women with normal values in the OGTT. To discriminate the rs1024611 and rs4586, rs2107538, rs2243250, rs2857261 and rs2254514 alleles, TaqMan Pre-Designed SNP Genotyping Assays were used. GDM was significantly associated with genotypes and alleles of the rs1024611 and rs4586 polymorphisms, while there was no statistically significant association between the rs2107538, rs2243250, rs2857261, and rs2254514 gene polymorphisms and GDM. In a multivariate regression analysis, age and BMI before pregnancy were independent significant predictors of a higher risk of GDM, while a lower number of G alleles rs1024611 was protective against GDM. Moreover, women with the GG rs1024611 and CC rs4586 genotype tended to have lower body mass and BMI increases during pregnancy, as well as lower newborn body mass. The results of our study suggest an association between gene polymorphisms and GDM.

show abstract

“…CCL2 считается ответственным за накопление макрофагов в жировой ткани. Предыдущие исследования показали, что повышенный уровень в сыворотке крови CCL2 у людей коррелирует с маркерами метаболического синдрома, ожирением, резистентностью к инсулину, диабету, гипертонией и увеличением концентрации триацилглерола в сыворотке [3]. В заключение следует отметить, что результаты нашей работы подтверждают предположение о влиянии полиморфизма генов CCL2, CXCL1, CCR5, CX3CR1, SAA1, CD4 на процессы, играющие важную роль в патогенезе воспаления жировой ткани.…”

Section: материалы и методыunclassified

Gene Polymorphism Analysis of Chemokines, Chemokine Receptors, Acute Phase Proteins, and Cd14 in Female Obesity Development

Кочетова¹,

Akhmadishina²,

Korytina³

et al. 2018

Med. immunol.

View full text Add to dashboard Cite

In the present study, we have investigated frequency of genotypes and functional alleles of genes encoding chemokines (CXCL12 rs1801157, CCL2 rs1024611), chemokine receptors (CCR5 del32, CX3CR1 rs3732378), acute phase proteins SAA rs1136743, and CD14 rs2569190 polymorphisms among Tatar obese or overweight women from the Republic of Bashkortostan.The group of patients comprised unrelated women with obesity (BMI ≥ 30 kg/m2, n = 225), females with overweight (BMI 25.0-29.9 kg/m2, n = 184), and control group of women (n = 327) BMI < 25.0 kg/m2. Genotyping was performed by PCR-RFLP analysis. Patients and controls differed in such parameters as body weight (p = 0.00001), BMI level (p = 0.001) and fasting glucose level (p = 0.0001).An association was revealed between obesity andAG-AAgenotypes (p = 0.007) andAallele (p = 0.003) of polymorphic locus rs3732378 ofCXCR1gene, as well asTTgenotype (p = 0.027) andTallele (p = 0.021) of polymorphic locus rs1136743 ofSAAgene. It has been shown that theAAgenotype of polymorphic locus rs3732378 of theCX3CR1gene is associated with increased body weight (p = 0.002) and elevated BMI (p = 0.018); theGGgenotype of polymorphic locus rs1024611 of theCCL2gene is associated with elevated fasting glucose level (p = 0.001).As based on clinical and genetic data and using logistic regression, some statistically significant differences were revealed, which allow to predict development of obesity in Tatar women.

show abstract

Increased circulating RANTES in type 2 diabetes

Cited by 20 publications

References 43 publications

Atorvastatin Decreased Circulating RANTES Levels in Impaired Glucose Tolerance Patients with Hypercholesterolemia: An Interventional Study

Atorvastatin Decreased Circulating RANTES Levels in Impaired Glucose Tolerance Patients with Hypercholesterolemia: An Interventional Study

CCL2, CCL5, IL4 and IL15 Gene Polymorphisms in Women with Gestational Diabetes Mellitus

Gene Polymorphism Analysis of Chemokines, Chemokine Receptors, Acute Phase Proteins, and Cd14 in Female Obesity Development

Contact Info

Product

Resources

About